If your institution uses the HemSys software and database, you can contribute to research!
What is a Multidisciplinary Consultation Meeting or MCM?
The Ellye Association, Together Leukemia Lymphoma Hope, and the specialized clinical research network on Lymphoma LYSA collaborated to explain in a short video how a Multidisciplinary Consultation Meeting (MCM) takes place.
This video is available on the LymphoSite website in the section ‘Diagnosis, After examinations, the MCM’: https://www.lymphosite.fr/diagnostic/5/apres-les-examens-la-rcp.html.
The information it contains applies to all hematologic diseases managed within the HemSys software.
“The data recorded for your care can aid research and the development of new therapeutic solutions in the field of hematology.
The software contains two main types of data, all of which are protected and secured:
– Identifiable data necessary for the doctors managing your care: only medical professionals handle this data.
– Non-identifiable data that does not allow for personal identification: a disease name, a numerical examination result, etc.
The reuse of non-identifiable data entered into HemSys enables doctors and researchers to study various hematological diseases. The HemSys database allows for concurrent sub-studies addressing specific research questions: number of new patients diagnosed per year, demographics of a pathology (distribution of ages and genders of patients), key biological markers, etc.”
What are the objectives of the studies conducted with data from the HemSys database?
The studies conducted using HemSys data will aim at improving medical practices, conducting research, fostering development, and fostering innovation in the field of hematology.
The studies or research will be reviewed by the HemSys governance to verify their scientific interest, the relevance of the methodology used, and the regulatory, legal, and technical feasibility, particularly regarding data security.
Study/Project Name | Description | Data Controller | Purpose of the Project | Document | |
Transferability of HemSys Results | Comparison of HemSys and PMSI data (national hospitalization database) to extrapolate the transferability of HemSys results at the regional and national levels | Academic | Validate the use of “real-world” data for research on hematological diseases | Information Letter_2023_PMSI | |
Marginal Zone Lymphoma | Statistical description of patients with Marginal Zone Lymphoma (MZL) in HemSys (G.Manson, C. Thieblemont) | Industrial | Analyze and understand patient management for a potential drug | Information Letter_2022_MZL | |
NGS Impact in CLL Management | NGS Impact in CLL Management (M. Ganard, C. Pastoret) – science thesis | Academic | Analyze and understand patient management | ||
Cold Agglutinins | Cold Agglutinins (P. Daufresne, T. Lamy) – science thesis | Academic | Analyze and understand patient management | ||
Relapse Hodgkin treated with BV + Benda | Relapse Hodgkin treated with BV + Benda (K. Bouabdallah) – under publication | Academic | Analyze and understand patient management | ||
Myelitis & Hodgkin’s Disease | Myelitis & Hodgkin’s Disease (K. Le Dû) – science thesis – under publication | Academic | Analyze and understand patient management | ||
Lymphoma & Lupus | Lymphoma & Lupus (JS. Allain) – science thesis – under publication | Academic | Analyze and understand patient management | ||
DLBCL & DHAP/DHAC/DHAOx | DLBCL & DHAP/DHAC/DHAOx (E. Gyan) – currently under publication | Academic | Analyze and understand patient management | ||
Myeloma & Bone Complications | Myeloma & Bone Complications (A. Meynier de Salinelles, O. Decaux) – science thesis – currently under publication | Academic | Analyze and understand patient management |